Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Debt to Equity (2016 - 2026)

Integra Lifesciences Holdings' Debt to Equity history spans 17 years, with the latest figure at $1.66 for Q4 2025.

  • On a quarterly basis, Debt to Equity rose 128.32% to $1.66 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.66, a 128.32% increase, with the full-year FY2025 number at $1.66, up 128.32% from a year prior.
  • Debt to Equity hit $1.66 in Q4 2025 for Integra Lifesciences Holdings, up from $1.65 in the prior quarter.
  • Over the last five years, Debt to Equity for IART hit a ceiling of $1.66 in Q4 2025 and a floor of $0.43 in Q4 2022.
  • Historically, Debt to Equity has averaged $0.76 across 5 years, with a median of $0.55 in 2023.
  • Biggest five-year swings in Debt to Equity: decreased 26.99% in 2021 and later soared 128.32% in 2025.
  • Tracing IART's Debt to Equity over 5 years: stood at $0.52 in 2021, then decreased by 17.15% to $0.43 in 2022, then grew by 21.63% to $0.52 in 2023, then skyrocketed by 39.63% to $0.73 in 2024, then surged by 128.32% to $1.66 in 2025.
  • Business Quant data shows Debt to Equity for IART at $1.66 in Q4 2025, $1.65 in Q3 2025, and $1.63 in Q2 2025.